212 related articles for article (PubMed ID: 12459731)
1. Molecular mechanisms of novel therapeutic approaches for multiple myeloma.
Hideshima T; Anderson KC
Nat Rev Cancer; 2002 Dec; 2(12):927-37. PubMed ID: 12459731
[TBL] [Abstract][Full Text] [Related]
2. On the Need for Phase III Studies of Risk-Adapted Therapy in Multiple Myeloma.
Voorhees P
Biol Blood Marrow Transplant; 2017 Feb; 23(2):181-182. PubMed ID: 27993621
[No Abstract] [Full Text] [Related]
3. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.
Hideshima T; Mitsiades C; Tonon G; Richardson PG; Anderson KC
Nat Rev Cancer; 2007 Aug; 7(8):585-98. PubMed ID: 17646864
[TBL] [Abstract][Full Text] [Related]
4. miRNAs and Multiple Myeloma: Focus on the Pathogenesis, Prognosis, and Drug Resistance.
Tavakoli Pirzaman A; Ebrahimi P; Hasanpour AH; Shakeri M; Babajani B; Pourali Ganji Z; Babaei H; Rahmati A; Hosseinzadeh R; Doostmohamadian S; Kazemi S
Technol Cancer Res Treat; 2023; 22():15330338231202391. PubMed ID: 37728167
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and Prognostic Value of PACAP in Multiple Myeloma.
Tóth T; Alizadeh H; Polgár B; Csalódi R; Reglődi D; Tamás A
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445974
[TBL] [Abstract][Full Text] [Related]
6. Lysosomal dysfunction in Schwann cells is involved in bortezomib-induced peripheral neurotoxicity.
Wu Z; Yan W; Wang K; Xu G; Zhu D; Li X; Wang H; Yang M; Zhang X; Wu J
Arch Toxicol; 2023 May; 97(5):1385-1396. PubMed ID: 36826473
[TBL] [Abstract][Full Text] [Related]
7. Expression of integrin β-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics.
Roy Choudhury S; Byrum SD; Alkam D; Ashby C; Zhan F; Tackett AJ; Van Rhee F
Clin Epigenetics; 2023 Feb; 15(1):18. PubMed ID: 36737807
[TBL] [Abstract][Full Text] [Related]
8. Recent Advances in the Treatment and Supportive Care of POEMS Syndrome.
Bou Zerdan M; George TI; Bunting ST; Chaulagain CP
J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498588
[TBL] [Abstract][Full Text] [Related]
9. Drug repositioning: Progress and challenges in drug discovery for various diseases.
Hua Y; Dai X; Xu Y; Xing G; Liu H; Lu T; Chen Y; Zhang Y
Eur J Med Chem; 2022 Apr; 234():114239. PubMed ID: 35290843
[TBL] [Abstract][Full Text] [Related]
10. Multiple Myeloma: Molecular Pathogenesis and Disease Evolution.
Heider M; Nickel K; Högner M; Bassermann F
Oncol Res Treat; 2021; 44(12):672-681. PubMed ID: 34749378
[TBL] [Abstract][Full Text] [Related]
11. Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients-a single-center retrospective study.
Regidor B; Goldwater MS; Wang J; Bujarski S; Swift R; Eades B; Emamy-Sadr M; Eshagian S; Schwartz G; Spektor TM; Berenson JR
Ann Hematol; 2021 Aug; 100(8):2061-2070. PubMed ID: 33987683
[TBL] [Abstract][Full Text] [Related]
12. Signaling Pathway Mediating Myeloma Cell Growth and Survival.
Hideshima T; Anderson KC
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33435632
[TBL] [Abstract][Full Text] [Related]
13. The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications.
Ogiya D; Liu J; Ohguchi H; Kurata K; Samur MK; Tai YT; Adamia S; Ando K; Hideshima T; Anderson KC
Blood; 2020 Nov; 136(20):2334-2345. PubMed ID: 32844992
[TBL] [Abstract][Full Text] [Related]
14. CAMKIIγ is a targetable driver of multiple myeloma through CaMKIIγ/ Stat3 axis.
Yang L; Wu B; Wu Z; Xu Y; Wang P; Li M; Xu R; Liang Y
Aging (Albany NY); 2020 Jul; 12(13):13668-13683. PubMed ID: 32658867
[TBL] [Abstract][Full Text] [Related]
15. Microfluidic Device for On-Chip Immunophenotyping and Cytogenetic Analysis of Rare Biological Cells.
M Weerakoon-Ratnayake K; Vaidyanathan S; Larky N; Dathathreya K; Hu M; Jose J; Mog S; August K; K Godwin A; L Hupert M; A Witek M; A Soper S
Cells; 2020 Feb; 9(2):. PubMed ID: 32102446
[TBL] [Abstract][Full Text] [Related]
16. Bone Marrow-Derived Mesenchymal Stromal Cells: A Novel Target to Optimize Hematopoietic Stem Cell Transplantation Protocols in Hematological Malignancies and Rare Genetic Disorders.
Crippa S; Santi L; Bosotti R; Porro G; Bernardo ME
J Clin Med; 2019 Dec; 9(1):. PubMed ID: 31861268
[No Abstract] [Full Text] [Related]
17. Activity of TAS4464, a novel NEDD8 activating enzyme E1 inhibitor, against multiple myeloma via inactivation of nuclear factor κB pathways.
Muraoka H; Yoshimura C; Kawabata R; Tsuji S; Hashimoto A; Ochiiwa H; Nakagawa F; Fujioka Y; Matsuo K; Ohkubo S
Cancer Sci; 2019 Dec; 110(12):3802-3810. PubMed ID: 31583781
[TBL] [Abstract][Full Text] [Related]
18. DCZ0814 induces apoptosis and G0/G1 phase cell cycle arrest in myeloma by dual inhibition of mTORC1/2.
Kong Y; Li B; Chang S; Gao L; Xu Z; He W; Yang G; Xie B; Chen G; Hu L; Lu K; Wang Y; Wu X; Zhu W; Shi J
Cancer Manag Res; 2019; 11():4797-4808. PubMed ID: 31213901
[No Abstract] [Full Text] [Related]
19. The Safety Profile of Concurrent Therapy for Multiple Myeloma in the Modern Era.
Resende Salgado L; Wang S; Adler A; Chang S; Ru M; Moshier E; Dharmarajan K; Jay Cho H; Bakst R
Adv Radiat Oncol; 2019; 4(1):112-117. PubMed ID: 30706018
[TBL] [Abstract][Full Text] [Related]
20. Galla Rhois water extract inhibits lung metastasis by inducing AMPK‑mediated apoptosis and suppressing metastatic properties of colorectal cancer cells.
Mun JG; Kee JY; Han YH; Lee S; Park SH; Jeon HD; Hong SH
Oncol Rep; 2019 Jan; 41(1):202-212. PubMed ID: 30365120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
